Yang-Mills instantons on cones and sine-cones over nearly K\"ahler manifolds

We present a unified eight-dimensional approach to instanton equations on several seven-dimensional manifolds associated to a six-dimensional homogeneous nearly K\"ahler manifold. The cone over the sine-cone on a nearly K\"ahler manifold has holonomy group Spin(7) and can be foliated by submanifolds with either holonomy group G_2, a nearly parallel G_2-structure or a cocalibrated G_2-structure. We show that there is a G_2-instanton on each of these seven-dimensional manifolds which gives rise to a Spin(7)-instanton in eight dimensions. The well-known octonionic instantons on R^7 and R^8 are contained in our construction as the special cases of an instanton on the cone and on the cone over the sine-cone, both over the six-sphere, respectively.Comment: 1+21 page

ELECTRON BEAM DIAGNOSTICS FOR FLASH II

Abstract Up to now, the FLASH linac serves one SASE undulator. The radiation produced can be guided to one of 5 beamlines. In order to increase the availability of the machine, a second undulator section, called FLASH II, will be built in the next 2 years to generate SASE light. A HHG laser will alternatively serve to produce seeded radiation in the undulators. The electron beam diagnostics in FLASH II has to enable the precise control of the beam position, size, timing, as well as the overlap of the electron beam with the HHG laser. Losses have to be kept under control, and the beam has to terminate safely in the beam dump. In comparison to FLASH, which was designed to run with rather high charge, the dynamic range of the diagnostics has to be between 0.1 to 1 nC, similar to the European XFEL. This paper gives an overview of the diagnostics for FLASH II

Instantons and Killing spinors

We investigate instantons on manifolds with Killing spinors and their cones. Examples of manifolds with Killing spinors include nearly Kaehler 6-manifolds, nearly parallel G_2-manifolds in dimension 7, Sasaki-Einstein manifolds, and 3-Sasakian manifolds. We construct a connection on the tangent bundle over these manifolds which solves the instanton equation, and also show that the instanton equation implies the Yang-Mills equation, despite the presence of torsion. We then construct instantons on the cones over these manifolds, and lift them to solutions of heterotic supergravity. Amongst our solutions are new instantons on even-dimensional Euclidean spaces, as well as the well-known BPST, quaternionic and octonionic instantons.Comment: 40 pages, 2 figures v2: author email addresses and affiliations adde

Homogeneous heterotic supergravity solutions with linear dilaton

I construct solutions to the heterotic supergravity BPS-equations on products of Minkowski space with a non-symmetric coset. All of the bosonic fields are homogeneous and non-vanishing, the dilaton being a linear function on the non-compact part of spacetime.Comment: 36 pages; v2 conclusion updated and references adde

Polarization multiplexed 16QAM transmission employing modified digital back-propagation

We experimentally demonstrate performance enhancements enabled by weighted digital back propagation method for 28 Gbaud PM-16QAM transmission systems, over a 250 km ultra-large area fibre, using only one back-propagation step for the entire link, enabling up to 3 dB improvement in power tolerance with respect to linear compensation only. We observe that this is roughly the same improvement that can be obtained with the conventional, computationally heavy, non-weighted digital back propagation compensation with one step per span. As a further benchmark, we analyze performance improvement as a function of number of steps, and show that the performance improvement saturates at approximately 20 steps per span, at which a 5 dB improvement in power tolerance is obtained with respect to linear compensation only. Furthermore, we show that coarse-step self-phase modulation compensation is inefficient in wavelength division multiplexed transmission

Analysis of the Fibroblast Growth Factor System Reveals Alterations in a Mouse Model of Spinal Muscular Atrophy

The monogenetic disease Spinal Muscular Atrophy (SMA) is characterized by a progressive loss of motoneurons leading to muscle weakness and atrophy due to severe reduction of the Survival of Motoneuron (SMN) protein. Several models of SMA show deficits in neurite outgrowth and maintenance of neuromuscular junction (NMJ) structure. Survival of motoneurons, axonal outgrowth and formation of NMJ is controlled by neurotrophic factors such as the Fibroblast Growth Factor (FGF) system. Besides their classical role as extracellular ligands, some FGFs exert also intracellular functions controlling neuronal differentiation. We have previously shown that intracellular FGF-2 binds to SMN and regulates the number of a subtype of nuclear bodies which are reduced in SMA patients. In the light of these findings, we systematically analyzed the FGF-system comprising five canonical receptors and 22 ligands in a severe mouse model of SMA. In this study, we demonstrate widespread alterations of the FGF-system in both muscle and spinal cord. Importantly, FGF-receptor 1 is upregulated in spinal cord at a pre-symptomatic stage as well as in a mouse motoneuron-like cell-line NSC34 based model of SMA. Consistent with that, phosphorylations of FGFR-downstream targets Akt and ERK are increased. Moreover, ERK hyper-phosphorylation is functionally linked to FGFR-1 as revealed by receptor inhibition experiments. Our study shows that the FGF system is dysregulated at an early stage in SMA and may contribute to the SMA pathogenesis

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron

The recurrent emerging of novel viral variants of concern (VOCs) with evasion of preexisting antibody immunity upholds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case numbers and maintains a persistent demand for updated therapies. We selected the patient-derived antibody CV38-142 based on its potency and breadth against the VOCs Alpha, Beta, Gamma, and Delta for preclinical development into a therapeutic. CV38-142 showed in vivo efficacy in a Syrian hamster VOC infection model after post-exposure and therapeutic application and revealed a favorable safety profile in a human protein library screen and tissue cross-reactivity study. Although CV38-142 targets the same viral surface as sotrovimab, which maintains activity against Omicron, CV38-142 did not neutralize the Omicron lineages BA.1 and BA.2. These results highlight the contingencies of developing antibody therapeutics in the context of antigenic drift and reinforce the need to develop broadly neutralizing variant-proof antibodies against SARS-CoV-2